# US 2023/0272033 A1 · Epha3 and multi-valent targeting of tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272033 A1
- Document ID: US20230272033A1
- Status: Published application
- Kind: A1
- Application number: 18/316,672
- Filed: 2023-05-12
- Published: 2023-08-31
- Earliest claimed: 2013-11-11
- Assignees: Wake Forest University Health Sciences
- Applicants: Wake Forest University Health Sciences
- Inventors: Waldemar Debinski; Carla Lema Tome; Sara Ferluga; Poonam S. Sonawane
- Web page: https://patentgrep.com/patent/US20230272033A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/5437: {IL-13}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/06: containing a lysosomal/endosomal localisation signal
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13Rα2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.

## Claims

### Claim 1

A construct comprising, in combination:
a ligand that binds to EphA2, EphA3, and EphB2; and
at least one effector molecule.

### Claim 2 (depends on 1)

The construct of claim 1, wherein said construct is a fusion protein and/or a covalent conjugate.

### Claim 3 (depends on 1)

The construct of claim 1, wherein said ligand is eA5, a mutant of eA5, or an EphA2, EphA3 and EphB2 binding fragment thereof.

### Claim 4 (depends on 3)

The construct of claim 3, wherein said eA5, mutant of eA5, or EphA2, EphA3 and EphB2 binding fragment thereof is glycosylated.

### Claim 5 (depends on 1)

The construct of claim 1, wherein said at least one effector molecule comprises a diphtheria toxin or a Pseudomonas exotoxin A.

### Claim 6 (depends on 1)

The construct of claim 1, wherein said construct further comprises:
a cytosol localization element covalently coupled between said ligand and said at least one effector molecule; and
a subcellular compartment localization signal element covalently coupled between said ligand and said at least one effector molecule.

### Claim 7 (depends on 6)

The construct of claim 6, wherein said subcellular compartment localization signal element is a nuclear localization element or a lysosomal localization element.

### Claim 8 (depends on 1)

A construct of claim 1, wherein said construct has the formula, from N terminus to C terminus, selected from the group consisting of:
A-B-C-D-E,
E-D-C-B-A,
A-B-D-C-E; and
E-C-D-B-A,
wherein:
A is said ligand that binds to EphA2, EphA3 and EphB2;
B is a linker;
C is a cytosol localization element;
D is optionally present and is a subcellular compartment localization signal element; and
E is said at least one effector molecule.

### Claim 9 (depends on 8)

The construct of claim 8, wherein each of A, C, and D, and optionally B and E, is a protein or peptide.

### Claim 10 (depends on 8)

The construct of claim 8, wherein E is a toxin or an amphipathic antimicrobial peptide.

### Claim 11 (depends on 10)

The construct of claim 10, wherein E is an amphipathic antimicrobial peptide comprising a sequence selected from the group consisting of: (KLAKLAK)2; (KLAKKLA)2; (KAAKKAA)2 and (KLGKKLG)2.

### Claim 12 (depends on 8)

The construct of claim 8, wherein D is present and is a nuclear localization element and wherein E is a radiopharmaceutical or a chemotherapeutic agent.

### Claim 13 (depends on 1)

A method of detecting EphA2, EphA3 and/or EphB2 expressing cells, comprising administering said construct of claim 1 to a cell or group of cells, wherein said construct comprises a detectable group, and detecting said detectable group.

### Claim 14 (depends on 1)

A method of delivering at least one effector molecule to a cell of interest, comprising:
contacting the construct of claim 1 to a cell of interest under conditions in which said construct is internalized therein.

### Claim 15 (depends on 14)

The method of claim 14, wherein said effector molecule is delivered to a subcellular compartment.

### Claim 16 (depends on 14)

The method of claim 14, wherein said subcellular compartment is the nucleus.

### Claim 17

A polypeptide comprising a mutant eA5, or an EphA2, EphA3 and/or EphB2 binding fragment thereof, or a nucleic acid encoding a polypeptide comprising a mutant eA5, or an EphA2, EphA3 and/or EphB2 binding fragment thereof.

### Claim 18 (depends on 17)

The polypeptide or nucleic acid of claim 17, wherein the mutant eA5 comprises a P123A, S125A and/or G127A mutation.
